Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer

Annals of Internal Medicine

Volumn 132, Issue 5, 2000, Pages 364-368

  Vadhan Raj, Saroj ^a   Verschraegen, Claire F ^b,d   Bueso Ramos, Carlos ^a,c   Broxmeyer, Hal E ^a   Kudelka, Andrzej P ^a,e   Freedman, Ralph S ^a,f   Edwards, Creighton L ^a,c   Gershenson, David ^b,f   Jones, Dennie ^a,c   Ashby, Mark ^a,c   Kavanagh, John J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GENENTECH INC   (United States)

^d Laboratory Medicine Patient Care Services

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; GYNECOLOGIC CANCER; HIGH RISK PATIENT; HUMAN; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0034050651     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-5-200003070-00005     Document Type: Article

References (20)

1. Crawford J, Ozer H. Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164-70.
2. Nemunaitis J. Rabinowe SN, Singer JW, Bierman PJ, Jose JM, Freedman AS, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991:324:1773-8.
3. Heyman MR, Schiffer CA. Platelet transfusion therapy for the cancer patient. Semin Oncol. 1990:17:198-209.
4. de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-MpI ligand. Nature. 1994:369:533-8.
5. Bartley TC, Bogenberger J, Hunt P, Li YS, Lu HS, Martin F, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 1994;77:1117-24.
6. Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Dort PJ, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994:369:565-8.
7. Wendung F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M. CMpI is a humoral regulator of megakaryocytopoiesis. Nature. 1994:369: 571-4.
8. Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med. 1997:336:404-9.
9. Vadhan-Raj S, Murray U, Bueso-Ramos C, Patel S, Reddy SP, Hoots WK, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med. 1997:126:673-81.
10. Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Grigg AP. et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood. 1997;89:3118-28.
11. Vadhan-Raj S, Patel S, Broxmeyer HE, Bueso-Ramos C, Reddy SP, papadopolous N, et al. Phase l-ll investigation of recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifosfamide (I) [Abstract]. Blood. 1996; 88(Suppl 1):448a.
12. Calvert AH, Lind MJ, Ghazal-Aswad S, Gumbrell L, Millward MJ, Bailey NP, et al. Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation study. Semin Oncol. 1994;21(Suppl 12): 1-6.
13. Rusthoven J, Levin L, Eisenhauer E, Mazurka J, Carmichael J, O'Connell G, et al. Two phase I studies of carboplatin dose escalation in chemotherapy-naive ovarian cancer patients supported with granulocyte-macrophage colony-stimulating factor. J Natl Cancer Inst. 1991;83: 1748-53.
14. Löwe J, Peterson M, Ramsey D, Wang J, Koren E. A novel bioassay for analysis of neutralizing anti-thrombopoietin antibodies [Abstract]. Blood. 1996;88(Suppl1):352a.
15. Vadhan-Raj S, Currie LM, Bueso-Ramos C, Livesey SA, Connor J. Enhanced retention of in vitro functional activity of platelets from recombinant human thrombopoietin-treated patients following long-term cryopreservation with a platelet-preserving solution (ThromboSol) and 2% DMSO. Br J Haematol. 1999:104:403-11.
16. Vadhan-Raj S, Kudelka AP, Garrison L, Gano J, Edwards CL, Freedman RS, et al. Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol. 1994; 12:707-14.
17. D'Hondt V, Weynants P, Humblet Y, Guillaume T, Canon JL, Beauduin M, et al. Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study. J Clin Oncol. 1993;11:2063-71.
18. Weber J, Yang JC. Topalian SL, Parkinson DR, Scwartzentruber DS, Ettinghausen SE. et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol. 1993:11:499-506.
19. Tepler I. Elias U Smith JW 2d, Hussein M, Rosen G, Chang AY, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood. 1996:87:3607-14.
20. Vadhan-Raj, S, Papadopoulos NE, Burgess MA, Linke KA, Patel SR, Hays C, et al. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. J Clin Oncol. 1994; 12: 715-24.